Efficacy of High-Dose Chemotherapy and Three-Dimensional Conformal Radiation for Atypical Teratoid/Rhabdoid Tumor: A Report From the Children’s Oncology Group Trial ACNS0333

Author:

Reddy Alyssa T.1,Strother Douglas R.2,Judkins Alexander R.3,Burger Peter C.4,Pollack Ian F.5,Krailo Mark D.6,Buxton Allen B.7,Williams-Hughes Chris7,Fouladi Maryam8,Mahajan Anita9,Merchant Thomas E.10,Ho Ben11,Mazewski Claire M.12,Lewis Victor A.2,Gajjar Amar13,Vezina Louis-Gilbert14,Booth Timothy N.15,Parsons Kerry W.16,Poss Vicky L.17,Zhou Tianni18,Biegel Jaclyn A.3,Huang Annie19

Affiliation:

1. Departments of Neurology and Pediatrics, University of California San Francisco, San Francisco, CA

2. Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada

3. Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles; Keck School of Medicine, University of Southern California, Los Angeles, CA

4. Department of Pathology, Johns Hopkins University, Baltimore, MD

5. Department Neurosurgery, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA

6. Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA

7. Children’s Oncology Group, Monrovia, CA

8. Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

9. Department of Radiation Oncology, Mayo Clinic, Rochester, MN

10. Department of Radiation Oncology, St Jude Children’s Research Hospital, Memphis, TN

11. Department of Cell Biology, Hospital for Sick Children, Toronto, Ontario, Canada

12. Aflac Cancer & Blood Disorders Center, Children's Healthcare of Atlanta; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA

13. Department of Oncology, St Jude Children's Research Hospital, Memphis, TN

14. Department of Radiology, The George Washington University School Medicine and Health Sciences, Washington, DC

15. Department of Radiology, University of Texas Southwestern, Dallas, TX

16. AstraZeneca Pharmaceuticals, Cambridge, UK

17. Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL

18. Department of Mathematics and Statistics, California State University at Long Beach, Long Beach, CA

19. Department of Pediatrics, Hospital for Sick Children, Arthur and Sonia Labatt Brain Tumour Research Centre, Toronto, Ontario, Canada

Abstract

PURPOSE Atypical teratoid/rhabdoid tumor (AT/RT) is an aggressive, early-childhood brain tumor without standard effective treatment. To our knowledge, we conducted the first AT/RT-specific cooperative group trial, ACNS0333, to examine the efficacy and safety of intensive postoperative chemotherapy and focal radiation to treat AT/RT. PATIENTS AND METHODS Patients from birth to 22 years of age with AT/RT were eligible. After surgery, they received 2 courses of multiagent chemotherapy, followed by 3 courses of high-dose chemotherapy with peripheral blood stem cell rescue and involved-field radiation therapy. Timing of radiation was based on patient age and disease location and extent. Central testing of tumor and blood for SMARCB1 status was mandated. Tumor molecular subclassification was performed retrospectively. The primary analysis was event-free survival (EFS) for patients < 36 months of age compared with a cooperative groups’ historical cohort. Although accrual was based on the therapeutic question, potential prognostic factors, including age, tumor location, M stage, surgical resection, order of therapy, germline status, and molecular subtype, were explored. RESULTS Of 65 evaluable patients, 54 were < 36 months of age. ACNS0333 therapy significantly reduced the risk of EFS events in patients < 36 months of age compared with the historical cohort ( P < .0005; hazard rate, 0.43; 95% CI, 0.28 to 0.66). Four-year EFS and overall survival for the entire cohort were 37% (95% CI, 25% to 49%) and 43% (95% CI, 31% to 55%), respectively. Timing of radiation did not affect survival, and 91% of relapses occurred by 2 years from enrollment. Treatment-related deaths occurred in 4 patients. CONCLUSION The ACNS0333 regimen dramatically improved survival compared with historical therapies for patients with AT/RT. Clinical characteristics and molecular subgrouping suggest prognostic differences. ACNS0333 results lay a foundation on which to build future studies and incorporate testing of new therapeutic agents.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3